论文部分内容阅读
目的探讨核因子КB受体活化因子配基(RANKL)在非小细胞肺癌(NSCLC)的表达以及与微血管密度(MVD)的关系。方法应用免疫组织化学的方法检测50例NSCLC中RANKL和CD34的表达。结果①RANKL在非小细胞肺癌中阳性表达率为62.0%(31/50),其中肺腺癌和肺鳞癌的RANKL阳性表达率分别为73.3%(22/30),45.0%(9/20),肺腺癌的RANKL蛋白阳性表达率显著高于肺鳞癌的RANKL阳性表达率(P<0.05)。②RANKL阳性组的MVD值高于RANKL阴性组,差异有显著性(P<0.05)。结论RANKL在非小细胞肺癌组织中的表达增高,可能在促进肿瘤血管的生成方面起着重要的作用。
Objective To investigate the expression of RANKL in non-small cell lung cancer (NSCLC) and its relationship with microvessel density (MVD). Methods Immunohistochemistry was used to detect the expression of RANKL and CD34 in 50 cases of NSCLC. Results ① The positive rate of RANKL expression in non-small cell lung cancer was 62.0% (31/50). The positive expression rates of RANKL in lung adenocarcinoma and squamous cell carcinoma were 73.3% (22/30) and 45.0% (9/20), respectively The positive expression rate of RANKL in lung adenocarcinoma was significantly higher than that in lung squamous cell carcinoma (P <0.05). ② The MVD of the RANKL-positive group was higher than that of the RANKL-negative group (P <0.05). Conclusion The increased expression of RANKL in non-small cell lung cancer may play an important role in promoting tumor angiogenesis.